Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImpedimedASX:IPD -8.33% EV-to-OCF is -1.55 as of Jul. 20, 2026. The stock has 6 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Impedimed ranks better than 66% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Impedimed's Enterprise Value is A$24.68 Mil.
Impedimed's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-15.88 Mil. Therefore, Impedimed's EV-to-OCF for today is -1.55.
The historical rank and industry rank for Impedimed's EV-to-OCF or its related term are showing as below:
ASX:IPD'
s EV-to-OCF Range Over the Past 10 Years
Min: -21.44 Med: -5.12 Max: -0.13
Current: -1.55
During the past 13 years, the highest EV-to-OCF of Impedimed was -0.13. The lowest was -21.44. And the median was -5.12.
ASX:IPD's EV-to-OCF is ranked better than 66% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.76
vs ASX:IPD: -1.55
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Impedimed's share price for today is A$0.0055.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Impedimed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Impedimed EV-to-OCF Related Terms
Impedimed EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Impedimed's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Impedimed's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impedimed EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Impedimed's EV-to-OCF falls into.
Impedimed's current Enterprise Value is A$24.68 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Impedimed's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-15.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impedimed (ASX:IPD) has a EV-to-OCF of -1.55 as of Jul. 20, 2026. According to the industry distribution chart, Impedimed ranks #290 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 34%.
Is Impedimed's EV-to-OCF too high?
Impedimed's current EV-to-OCF is -1.55. Based on the distribution chart, Impedimed ranks #290 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Impedimed's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Impedimed ranks #290 out of 853 companies for EV-to-OCF. This puts Impedimed in the upper half of its industry. The industry median EV-to-OCF is 7.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.76, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impedimed's current EV-to-OCF is -1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.09, compared to a current price of A$0.01 — trading 93.9% below its estimated fair value. The current EV-to-OCF is -1.55. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current EV-to-OCF is -1.55 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IPD has been successfully added to your 
